1. Home
  2. Events
  3. Kansai Life Science Accelerator Program 2022 Innovation Showcase

Kansai Life Science Accelerator Program 2022 Innovation Showcase

Kansai Life Science Accelerator Program, an accelerator program for Japanese life science startup companies, invites you to this Innovation Showcase featuring 3 Japanese life science startups that participated in the 2022 program.
This year, showcase will be held jointly with California acceleration program with 6 startups. Please participate and connect with 9 cutting-edge startups to see what they have accomplished through CLS accelerator program!

Date and Time
December13, 2022, 5:00pm - 8:30 pm (PST)
* Online Session: 5:30pm – 7:45pm
December 14, 2022 10:00am – 1:30pm (JST)
* Online Session: 10:30am – 12:45pm
Event Format
In-person & Online
Free of charge
Registration for In-Person Attendees:
URL: https://www.eventbrite.com/e/fast-fall-closing-showcase-tickets-444323442377
Venue:CLS Headquarters - Lighthouse Café Map
Address: 685 Gateway Boulevard South San Francisco, CA 94080 USA
Registration for on-line participants:
URL: https://www.eventbrite.com/e/fast-fall-innovation-showcase-kansai-tickets-460422424867?aff=erelpanelorg


5:00-5:30pm Registration
5:30-5:35pm Welcome remarks – Ms. Sibylle Hauser (CLS)
5:35-5:40pm Keynote Presentation
Ashley Zehnder, Founder and CEO, Fauna Bio
5:40-5:45pm Break
5:45-7:40pm Startup Pitch Session
7.40-7:45pm Closing Remarks – Ms. Shikha Sharma (CLS)
7:45-8:30pm Reception (at lighthouse)
○Aikomi Co., Ltd.:
Develop AI driven digital therapeutic platform for personalized multi sense cognitive stimulation for people with dementia and their families and caregivers.
○CellFiber Co., Ltd.:
Provide cell therapy through mass bio-production of cells using cell culture platform technology.
○miibio, Inc.:
Utilizing photo switch proteins for the wider biotech market and create new industries by providing research tools, gene therapy and regenerative medicine to improve bio productions.
California Program
Acelot developa small molecules that inhibit multiple toxic protein species associated with neurodegenerative diseases.
○Angeles Therapeutics:
Angeles Therapeutics is a next generation cell therapy company. With its CAR design, it has solved the problem of lack of efficacy of CARs in solid tumors.
○Biomark Onology:
BioMark Oncology is a translationally enabled, preclinical-stage pharmaceutical company developing a platform to further the use of response biomarkers in clinical trials.
○f5 Therapeutics:
f5 Therapeutics Incorporated is a privately-held pharmaceutical company that is expanding the scope of degradable targets in the targeted protein degradation arena via our NExMods™ platform.
○Tab Diagnostic:
Tab Diagnostics is a non-invasive diabetes testing and monitoring company developing the first portable saliva-based, graphene field-effect transistor assay to measure Glycated Albumin (diabetic biomarker).
○Weatherwax Biotechnologies:
Weatherwax Biotechnologies is a seed-stage startup developing the next generation of induced-proximity medicines.